Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Recruiting now

Conditions studied: Retroperitoneal Liposarcoma

In brief

The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.

Key facts

Study ID

NCT07377747

Run by

Australia and New Zealand Sarcoma Association

People needed

100

Starts

2024-09-05

Expected to finish

2032-12-01

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)
• No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease
• Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only
• Sarcoma not originating from bone or abdominal or gynecological viscera
• Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)
• WHO performance status 0-2
• American Society of Anaesthesiologist (ASA) score 1-3
• No prior RT for the retroperitoneal liposarcoma
• Prior systemic therapy is allowed
• No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)
• Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment
• Patient deemed able to comply with study requirements according to investigator evaluation
• Signed, IRB-approved written informed consent

You may not qualify if…

• Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team
• Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible
• Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease
• Myxoid liposarcoma histology
• Pregnancy

Where it is running

• Emory Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
• Institut Curie Hospital — Paris, France (enrolling)
• The Netherlands Cancer Institute — Amsterdam, North Holland, Netherlands (enrolling)
• OSU James Hospital — Columbus, Ohio, United States (enrolling)
• MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Chris O'Brien Lifehouse — Camperdown, New South Wales, Australia (enrolling)
• Prince of Wales Hospital — Randwick, New South Wales, Australia (enrolling)
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (enrolling)
• UZ Leuven — Leuven, Flemish Brabant, Belgium (enrolling)
• A.C.Camargo Cancer Center - Fundacao Antonio Prudente — Liberdade, São Paulo, Brazil (enrolling)
• The Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Maria Sklodowska-Curie National Research Institute of Oncology — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.